A Life Science Company

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer

79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications / Similar ORR of 75% in patients with brain metastases1, adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years1 / Largest dataset with longest follow-up of any TRK inhibitor illustrates favourable safety profile across ages and tumour types Read more

Bayer Fund shares over $100,000 in funding with students through its Opportunity Scholarship Program

67 Canadian students pursuing post-secondary education in agriculture and food-related disciplines Read more

Bayer completes sale of iconic Coppertone™ brand to Beiersdorf

Divestiture enables Bayer to focus on core OTC business Read more

Ertharin Cousin to become member of Bayer AG Supervisory Board

Read more